NZ334035A - Use of endokine alpha antagonists to diagnose and treat TNF-related disorders - Google Patents

Use of endokine alpha antagonists to diagnose and treat TNF-related disorders

Info

Publication number
NZ334035A
NZ334035A NZ334035A NZ33403596A NZ334035A NZ 334035 A NZ334035 A NZ 334035A NZ 334035 A NZ334035 A NZ 334035A NZ 33403596 A NZ33403596 A NZ 33403596A NZ 334035 A NZ334035 A NZ 334035A
Authority
NZ
New Zealand
Prior art keywords
amino acid
endokine alpha
acid sequence
cytokine
seq
Prior art date
Application number
NZ334035A
Other languages
English (en)
Inventor
Guo-Liang Yu
Jian Ni
Craig A Rosen
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Priority to NZ334035A priority Critical patent/NZ334035A/xx
Publication of NZ334035A publication Critical patent/NZ334035A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/525Tumour necrosis factor [TNF]
    • C07K14/5255Lymphotoxin [LT]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NZ334035A 1996-08-16 1996-08-16 Use of endokine alpha antagonists to diagnose and treat TNF-related disorders NZ334035A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ334035A NZ334035A (en) 1996-08-16 1996-08-16 Use of endokine alpha antagonists to diagnose and treat TNF-related disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US1996/013282 WO1998007880A1 (en) 1996-08-16 1996-08-16 Human endokine alpha
NZ334035A NZ334035A (en) 1996-08-16 1996-08-16 Use of endokine alpha antagonists to diagnose and treat TNF-related disorders

Publications (1)

Publication Number Publication Date
NZ334035A true NZ334035A (en) 2000-09-29

Family

ID=22255618

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ334035A NZ334035A (en) 1996-08-16 1996-08-16 Use of endokine alpha antagonists to diagnose and treat TNF-related disorders

Country Status (11)

Country Link
EP (2) EP2025682A3 (enExample)
JP (1) JP2000516474A (enExample)
KR (1) KR20010102191A (enExample)
AT (1) ATE412740T1 (enExample)
AU (4) AU731123B2 (enExample)
CA (1) CA2264200A1 (enExample)
DE (1) DE69637734D1 (enExample)
DK (1) DK0961831T3 (enExample)
ES (1) ES2316153T3 (enExample)
NZ (1) NZ334035A (enExample)
WO (1) WO1998007880A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7597886B2 (en) 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US6713061B1 (en) 1996-03-12 2004-03-30 Human Genome Sciences, Inc. Death domain containing receptors
WO1997033904A1 (en) 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Death domain containing receptors
US7357927B2 (en) 1996-03-12 2008-04-15 Human Genome Sciences, Inc. Death domain containing receptors
US6635743B1 (en) 1996-03-22 2003-10-21 Human Genome Sciences, Inc. Apoptosis inducing molecule II and methods of use
US7964190B2 (en) 1996-03-22 2011-06-21 Human Genome Sciences, Inc. Methods and compositions for decreasing T-cell activity
US6406867B1 (en) 1996-08-16 2002-06-18 Human Genome Sciences, Inc. Antibody to human endokine alpha and methods of use
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
WO2001040464A1 (en) * 1999-11-30 2001-06-07 Genentech, Inc. Interleukin-1-receptor associated kinase-3 (irak3) and its use in promotion or inhibition of angiogenesis and cardiovascularization
WO2000073445A2 (en) * 1999-06-02 2000-12-07 Genentech, Inc. Interleukin-1-receptor associated kinase-3 (irak3)
US6689607B2 (en) 1997-10-21 2004-02-10 Human Genome Sciences, Inc. Human tumor, necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
US6503184B1 (en) 1997-10-21 2003-01-07 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
CA2308365A1 (en) * 1997-11-18 1999-05-27 Genentech, Inc. Dna19355 polypeptide, a tumor necrosis factor homolog
JP2002537769A (ja) * 1999-02-26 2002-11-12 ヒューマン ジノーム サイエンシーズ, インコーポレイテッド ヒトエンドカインαおよび使用方法
AU6391000A (en) * 1999-07-28 2001-02-19 Genentech Inc. Method of preventing the injury or death of retinal cells and treating ocular diseases
CA2405550A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
WO2001096528A2 (en) 2000-06-15 2001-12-20 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
EP2275449B1 (en) 2000-06-16 2016-09-28 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to BLyS
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
US20030091565A1 (en) 2000-08-18 2003-05-15 Beltzer James P. Binding polypeptides and methods based thereon
DK1572874T3 (da) 2001-05-25 2013-12-16 Human Genome Sciences Inc Antistoffer, der immunospecifikt binder til TRAIL receptorer
AU2002364586A1 (en) 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
EA015860B1 (ru) 2005-10-13 2011-12-30 Хьюман Дженом Сайенсиз, Инк. Способы лечения аутоиммунных заболеваний при использовании антагониста нейтрокина-альфа
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
US8211649B2 (en) 2006-03-31 2012-07-03 Human Genome Sciences, Inc. Methods of diagnosing and prognosing hodgkin's lymphoma
WO2010036986A2 (en) 2008-09-26 2010-04-01 Tocagen Inc. Recombinant vectors
AR084141A1 (es) 2010-11-19 2013-04-24 Imai Toshio Anticuerpos neutralizadores anti-ccl20
NL2005893C2 (nl) 2010-12-22 2012-06-25 Vanderlande Ind Bv Systeem en werkwijze voor het bufferen van bagagestukken.
EP2909324B1 (en) 2012-10-25 2020-02-26 Tocagen Inc. Retroviral vector with mini-promoter cassette
MA41460A (fr) 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US599817A (en) * 1898-03-01 Cash-register
US4433092A (en) 1981-03-09 1984-02-21 Champion Spark Plug Company Green ceramic of lead-free glass, conductive carbon, silicone resin and AlPO4, useful, after firing, as an electrical resistor
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3472793D1 (en) * 1983-12-26 1988-08-25 Asahi Chemical Ind A novel physiologically active polypeptide
US5288852A (en) * 1984-03-06 1994-02-22 Dainippon Pharmaceutical Co., Ltd. Human tumor necrosis factor polypeptides
DE3586772T2 (de) 1984-07-24 1993-03-04 Coselco Mimotopes Pty Ltd Verfahren zur bestimmung von mimotopen.
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4631211A (en) 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
EP0232262A4 (en) 1985-08-15 1989-09-19 Stauffer Chemical Co TRYPTOPHANE GENERATING MICROORGANISM.
EP0212489B1 (en) * 1985-08-16 1994-11-30 The Rockefeller University Anabolic activity modulator and uses thereof
US4870163A (en) 1985-08-29 1989-09-26 New York Blood Center, Inc. Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor
LU86128A1 (fr) 1985-10-18 1987-06-02 Vander Poorten Henri Procede permettant l'impression ou le revetement de ceramique simultanement a son electroformage et conduisant en monocuisson a des produits decoratifs ou techniques
WO1987002671A1 (en) 1985-11-01 1987-05-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
JP2647427B2 (ja) * 1987-04-24 1997-08-27 帝人株式会社 被検者の病態の判定のための検出方法、モノクロ−ナル抗体および検出キット
EP0394827A1 (en) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
DK0464533T3 (da) 1990-06-28 1999-04-26 Gen Hospital Corp Fusionsproteiner med immunglobulindele, deres fremstilling og anvendelse
US5480971A (en) 1993-06-17 1996-01-02 Houghten Pharmaceuticals, Inc. Peralkylated oligopeptide mixtures
AU708972B2 (en) * 1994-11-07 1999-08-19 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US5998171A (en) * 1996-08-16 1999-12-07 Human Genome Sciences, Inc. Polynucleotides encoding human endokine alpha

Also Published As

Publication number Publication date
AU5393701A (en) 2001-08-16
EP0961831A1 (en) 1999-12-08
ES2316153T3 (es) 2009-04-01
EP2025682A3 (en) 2009-06-17
JP2000516474A (ja) 2000-12-12
EP2025682A2 (en) 2009-02-18
AU731123B2 (en) 2001-03-22
DK0961831T3 (da) 2009-01-12
EP0961831B1 (en) 2008-10-29
AU764278B2 (en) 2003-08-14
AU2007202630B2 (en) 2010-04-22
ATE412740T1 (de) 2008-11-15
AU2007202630A1 (en) 2007-06-28
AU2007202630B8 (en) 2010-08-19
EP0961831A4 (en) 2002-06-12
KR20010102191A (ko) 2001-11-15
CA2264200A1 (en) 1998-02-26
AU2003257892A1 (en) 2003-11-20
WO1998007880A1 (en) 1998-02-26
AU6847896A (en) 1998-03-06
DE69637734D1 (de) 2008-12-11

Similar Documents

Publication Publication Date Title
NZ334035A (en) Use of endokine alpha antagonists to diagnose and treat TNF-related disorders
Cox Endogenous opioid peptides: a guide to structures and terminology
Weining et al. A chicken homolog of mammalian interleukin‐1β: cDNA cloning and purification of active recombinant protein
Wagener et al. Primary structure of matrilin-3, a new member of a family of extracellular matrix proteins related to cartilage matrix protein (matrilin-1) and von Willebrand factor
CA2343655A1 (en) Interleukin 17-like receptor protein
EP0782584A1 (en) Il-1 receptor antagonists with enhanced inhibitory activity
DE10075019I2 (de) Neue Proteine mit TNF-Hemmender Wirkung und ihre Herstellung.
CA2266439A1 (en) Neutrokine .alpha.
EP1283264A3 (en) Interleukin-3 (IL-3) mutant polypeptides
AU7608898A (en) Ntn-2 member of tnf ligand family
DE951551T1 (de) Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie
MX9703476A (es) Factor derivado de neuronas sensoriales y motoras (smdf).
RU95117238A (ru) Нуклеиновая кислота, рекомбинантная плазмида, рекомбинантный вектор, белок, синтетический пептид, химерная молекула, иммуногенная композиция, антисыворотка или антитела
KR970701776A (ko) 형질전환 성장 인자 알파 에이치1(Transforming growth factor alpha H1)
AU7713098A (en) Ntn-2 member of tnf ligand family
RU99107759A (ru) Применение антагонистов лептина для лечения резистентности к инсулину при диабете ii типа
BG102973A (en) LIGAND RET (RetL) FOR THE STIMULATION OF THE NERVE AND RENAL GROWTH
CA2338186A1 (en) Tumor necrosis factor-gamma
AU2028497A (en) Metabotropic gaba{b} receptors, receptor-specific ligands and their uses
CA2378543A1 (en) Modified human granulocyte-colony stimulating factor and process for producing same
RU2002103159A (ru) Модифицированный колониестимулирующий фактор гранулоцитов человека и способ его получения, днк, экспрессирующий вектор
EP1092727A3 (en) G-protein receptor
US6447996B1 (en) Galanin receptors, nucleic acids, transformed cells and uses thereof
KR940005798A (ko) 지방세포화 억제 인자 유도체, 그의 제조방법 및 용도
Yang et al. Solution structure of the recombinant human oncoprotein p13 MTCP1

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
EXPY Patent expired